ライフサイエンスコーパス: LGV

1 LGV cure (primary endpoint) was defined as resolution of

2 LGV cure on a modified intention-to-treat analysis (prim

3 LGV-MC occurred in 70 of 72 (97%) vs 15 of 15 (100%) in

4 mbinant strains D/B120, G/UW-57, E/Bour, and LGV-98 identified in this study.

5 correctly identified the DNA from D to K and LGV reference strains and did not cross-react with the D

6 manifested itself in ocular, urogenital and LGV C. trachomatis strains, including the epidemic LGV s

7 the 15 serovars into ocular, urogenital, and LGV groups, and both proteins have been localized to the

8 ced two isolates from the remaining biotype, LGV, a long-term laboratory passaged strain and the rece

9 mydia trachomatis strains (L2/434/Bu [biovar LGV] and E/DK20/ON [biovar trachoma]) to induce putative

10 echnologies to show that the recent clinical LGV isolate causing proctitis is unlikely to be a newly

11 Newer molecular tests to confirm LGV infection are sensitive and specific, but are genera

12 irically with a recommended regimen to cover LGV infection.

13 lution of symptoms at week 6 (clinical cure, LGV-CC), with an additional supporting negative rectal p

14 ction (PCR) at week 4 (microbiological cure, LGV-MC), if available.

15 trachomatis strains, including the epidemic LGV serotype L2b.

16 ry passaged strain and the recent "epidemic" LGV isolate-causing proctitis.

17 21 days) remains the treatment of choice for LGV.

18 r symptoms of proctitis should be tested for LGV, or if confirmatory testing is not available, should

19 thromycin 1 g for 3 weeks as a treatment for LGV proctitis.

20 Tarps from LGV strains contained the highest number of tyrosine-ric

21 hough with lower sensitivity than they lysed LGV-infected target cells.

22 um (LGV) recombinant strain possessing a non-LGV ompA genotype.

23 rent pathologies associated with LGV and non-LGV strains.

24 e most divergent, compared to ocular and non-LGV urogenital disease groups.

25 No such associations were found for non-LGV-inducing strains.

26 ranuloma venereum (LGV); 1 plausible case of LGV was found by MIF.

27 With the exception of LGV-inducing strains, no evidence was found that differe

28 commonly reported clinical manifestations of LGV, with symptoms resembling those of inflammatory bowe

29 A simplex QTL allele was found on LGV of Stirling close to marker STM3179, which was assoc

30 there was no significant effect of a QTL on LGV, but a duplex QTL allele for resistance was found on

31 indings of an extensive literature review on LGV clinical presentation, diagnosis, and treatment that

32 confirmed these results using group-specific LGV real-time PCR and restriction fragment length polymo

33 alternative treatment option for symptomatic LGV proctitis and provides the rationale for future rand

34 metabolism was essential to induction by the LGV strain.

35 The assay also identified the LGV-II genotype in 24 of 48 rectal swab specimens contai

36 Although the genome of the LGV strain shows no additional genes that could account

37 spite minimal chromosomal polymorphisms, the LGV strain L2(25667R) was indistinguishable from plasmid

38 d serotypes D-K are noninvasive, whereas the LGV strains are invasive, causing a disseminating infect

39 B4855 are associated with factors mapping to LGV and LGX.

40 itative proteomic analysis of C. trachomatis LGV-L2 EB and RB forms.

41 the predicted proteins in the C. trachomatis LGV-L2 proteome.

42 f elementary bodies of Chlamydia trachomatis LGV serovar L2 and mass spectrometry to identify the lab

43 dia), and invasive lymphogranuloma venereum (LGV) and the murine strain Chlamydia muridarum share 99%

44 both trachoma and lymphogranuloma venereum (LGV) biovars from temporally and geographically diverse

45 ular, genital, and lymphogranuloma venereum (LGV) clinical isolates demonstrated an evolutionary rela

46 Lymphogranuloma venereum (LGV) has emerged as an important cause of proctitis and

47 Lymphogranuloma venereum (LGV) is a sexually transmitted infection caused by Chlam

48 amydia trachomatis lymphogranuloma venereum (LGV) recombinant strain possessing a non-LGV ompA genoty

49 differentiates the lymphogranuloma venereum (LGV) serovar from other serovars and may contribute the

50 Lymphogranuloma venereum (LGV) serovars were the most closely related for the pmp

51 Men with lymphogranuloma venereum (LGV)-inducing strains were more likely to be infected wi

52 serotypes D-K and lymphogranuloma venereum (LGV).

53 three genovars of lymphogranuloma venereum (LGV).

54 nital disease, and lymphogranuloma venereum (LGV).

55 lly diagnosed with lymphogranuloma venereum (LGV); 1 plausible case of LGV was found by MIF.

56 C. trachomatis (lymphogranuloma venereum [LGV])-elicited immune murine spleen cells lysed target c

57 te the different pathologies associated with LGV and non-LGV strains.

58 One hundred and twenty-five individuals with LGV clinical proctitis were included.

59 ry relationship with disease phenotype, with LGV and ocular isolates branched into clades that were s